Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Are we spending too much money on cancer drugs?

November is classically the month where immunotherapy takes center stage, especially at the annual conference of the Society for Immunotherapy of …

POPULAR TAGS

Medulloblastoma orphan drug designation for Oncurious

Written by DS on in the category news with the tags , .


Oncurious, an emerging oncology company focused on the development of innovative orphan drugs for the treatment of pediatric tumors, announces that the European Commission has confirmed the orphan drug designation for TB-403 for medulloblastoma. Today's decision by the EC follows the earlier positive opinion issued by the European Medicine Agency (EMA).

TB-403 is a humanized monoclonal antibody against placental growth factor (PlGF). PlGF is expressed in several types of cancer, including medulloblastoma. In medulloblastoma patients, high expression of the PlGF receptor neuropilin 1 has been shown to correlate with poor overall patient survival.

An orphan drug designation is for "medicines to be developed for the diagnosis, prevention or treatment of rare diseases that are life-threatening or very serious".

Today's confirmation by the EC follows an earlier in-depth review and positive opinion on the drug candidate by the EMA Committee for Orphan Medicinal Products (COMP). The COMP gathers a group of experts chosen on the strength of their qualifications and a number of patient organization representatives. Altogether, the COMP assesses the potential incremental benefits of a drug candidate versus existing treatments.

TB-403 is currently being evaluated in a Phase I/IIa clinical trial for treatment of medulloblastoma, a rare, life-threatening pediatric cancer.

The clinical trial is being conducted in partnership with the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC). The Consortium is a collaboration of 25 US academic medical centers, teaching hospitals and other entities, with the purpose of facilitating and conducting collaborative research activities and investigations of new treatments for neuroblastoma, medulloblastoma and other pediatric cancers. NMTRC is headquartered in Grand Rapids, MI, USA.

ONCURIOUS nv is working with BioInvent International AB as a development partner for this project.

Patrik De Haes, MD, Executive Chairman of Oncurious NV comments: "We are very happy with today's news. Gaining this orphan-drug designation is an important validation of the TB-403's scientific rationale and preclinical data. It also offers very valuable potential benefits including protocol assistance and fee waivers, as well as 10-year market exclusivity once the medicine is on the market in Europe."

Read more about: , .

RELATED ARTICLES
Are we spending too much money on cancer drugs?

November is classically the month where immunotherapy takes center stage, especially at the annual conference of the Society for Immunotherapy of …

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Biowin V-Bio Ventures Janssen Itera Life Science UGent Flanders.bio Turnstone XpandInnovation KU Leuven GSK

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.